Plasma sTNFR1 and IL8 for prognostic enrichment in sepsis trials: a prospective cohort study.

Autor: Anderson BJ; Division of Pulmonary, Allergy and Critical Care Medicine, Perelman School of Medicine, University of Pennsylvania, 3400 Spruce Street, 5036 Gates Building, Philadelphia, PA, 19104, USA. brian.anderson@uphs.upenn.edu., Calfee CS; Division of Pulmonary and Critical Care Medicine, University of California San Francisco, San Francisco, USA., Liu KD; Division of Pulmonary and Critical Care Medicine, University of California San Francisco, San Francisco, USA., Reilly JP; Division of Pulmonary, Allergy and Critical Care Medicine, Perelman School of Medicine, University of Pennsylvania, 3400 Spruce Street, 5036 Gates Building, Philadelphia, PA, 19104, USA., Kangelaris KN; Division of Hospital Medicine, Department of Medicine, University of California San Francisco, San Francisco, USA., Shashaty MGS; Division of Pulmonary, Allergy and Critical Care Medicine, Perelman School of Medicine, University of Pennsylvania, 3400 Spruce Street, 5036 Gates Building, Philadelphia, PA, 19104, USA.; Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA., Lazaar AL; Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.; GlaxoSmithKline R&D, Brentford, UK., Bayliffe AI; GlaxoSmithKline R&D, Brentford, UK., Gallop RJ; Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.; Department of Mathematics, West Chester University, West Chester, USA., Miano TA; Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA., Dunn TG; Division of Pulmonary, Allergy and Critical Care Medicine, Perelman School of Medicine, University of Pennsylvania, 3400 Spruce Street, 5036 Gates Building, Philadelphia, PA, 19104, USA., Johansson E; Division of Pulmonary, Allergy and Critical Care Medicine, Perelman School of Medicine, University of Pennsylvania, 3400 Spruce Street, 5036 Gates Building, Philadelphia, PA, 19104, USA., Abbott J; Division of Pulmonary and Critical Care Medicine, University of California San Francisco, San Francisco, USA., Jauregui A; Division of Pulmonary and Critical Care Medicine, University of California San Francisco, San Francisco, USA., Deiss T; Division of Pulmonary and Critical Care Medicine, University of California San Francisco, San Francisco, USA., Vessel K; Division of Pulmonary and Critical Care Medicine, University of California San Francisco, San Francisco, USA., Belzer A; Division of Pulmonary and Critical Care Medicine, University of California San Francisco, San Francisco, USA., Zhuo H; Division of Pulmonary and Critical Care Medicine, University of California San Francisco, San Francisco, USA., Matthay MA; Division of Pulmonary and Critical Care Medicine, University of California San Francisco, San Francisco, USA., Meyer NJ; Division of Pulmonary, Allergy and Critical Care Medicine, Perelman School of Medicine, University of Pennsylvania, 3400 Spruce Street, 5036 Gates Building, Philadelphia, PA, 19104, USA., Christie JD; Division of Pulmonary, Allergy and Critical Care Medicine, Perelman School of Medicine, University of Pennsylvania, 3400 Spruce Street, 5036 Gates Building, Philadelphia, PA, 19104, USA.; Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.
Jazyk: angličtina
Zdroj: Critical care (London, England) [Crit Care] 2019 Dec 09; Vol. 23 (1), pp. 400. Date of Electronic Publication: 2019 Dec 09.
DOI: 10.1186/s13054-019-2684-2
Abstrakt: Background: Enrichment strategies improve therapeutic targeting and trial efficiency, but enrichment factors for sepsis trials are lacking. We determined whether concentrations of soluble tumor necrosis factor receptor-1 (sTNFR1), interleukin-8 (IL8), and angiopoietin-2 (Ang2) could identify sepsis patients at higher mortality risk and serve as prognostic enrichment factors.
Methods: In a multicenter prospective cohort study of 400 critically ill septic patients, we derived and validated thresholds for each marker and expressed prognostic enrichment using risk differences (RD) of 30-day mortality as predictive values. We then used decision curve analysis to simulate the prognostic enrichment of each marker and compare different prognostic enrichment strategies.
Measurements and Main Results: An admission sTNFR1 concentration > 8861 pg/ml identified patients with increased mortality in both the derivation (RD 21.6%) and validation (RD 17.8%) populations. Among immunocompetent patients, an IL8 concentration > 94 pg/ml identified patients with increased mortality in both the derivation (RD 17.7%) and validation (RD 27.0%) populations. An Ang2 level > 9761 pg/ml identified patients at 21.3% and 12.3% increased risk of mortality in the derivation and validation populations, respectively. Using sTNFR1 or IL8 to select high-risk patients improved clinical trial power and efficiency compared to selecting patients with septic shock. Ang2 did not outperform septic shock as an enrichment factor.
Conclusions: Thresholds for sTNFR1 and IL8 consistently identified sepsis patients with higher mortality risk and may have utility for prognostic enrichment in sepsis trials.
Databáze: MEDLINE
Externí odkaz: